. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Int J Drug Policy. 2015 Aug 20;26(10):1014–1019. doi: 10.1016/j.drugpo.2015.08.008

Table 2.

On-treatment Characteristics of 50 HCV-infected Patients Treated On-site with Triple Therapy at Opiate Agonist Treatment Program

Characteristic	N (%) or Mean (± SD)

Active drug use during treatment ⁺
Used during treatment	22/49 (45)
No use during treatment	27/49 (55)

Model of care
Group treatment	38 (76)
Individual treatment	12 (24)

Directly observed treatment
Pegylated interferon only	44 (88)
Pegylated interferon ⁺ oral meds	6 (12)

DAA Adherence⁺	90.1 ± 0.15
< 90%	13 (29)
≥ 90%	32 (71)

Ribavirin Adherence⁺	91.8 ± 0.15
< 90%	10 (21)
≥ 90%	37 (79)

⁺

missing data